Target Complement system
Aus coViki
(Unterschied zwischen Versionen)
K |
|||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA Biologicals}} | ||
| + | |||
{{tp|p=32360516|t=ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |pdf=|usr=}} | {{tp|p=32360516|t=ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |pdf=|usr=}} | ||
{{tp|p=32329881|t=2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience |pdf=|usr=}} | {{tp|p=32329881|t=2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience |pdf=|usr=}} | ||
Aktuelle Version vom 18. Januar 2021, 20:48 Uhr
| PHA Biologicals |
32360516 ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
32329881 2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience
32327719 ä. Complement as a target in COVID-19?
| 32271624 2020. Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? |
32495372 2020. Terminal complement inhibition dampens the inflammation during COVID-19.
32417135 2020. Complement activation in patients with COVID-19: A novel therapeutic target.
32581810 2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.
32430402 2020. Could severe COVID-19 be considered a complementopathy?
